FDA’s New Oncology Office May Not Include Skin Cancer Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Skin cancer agents are likely to remain in the Division of Dermatologic & Dental Drug Products, FDA’s Colangelo says. It is “undecided” whether prostate cancer agents will be shifted to the new Office of Oncology Drug Products.